WO2016004911A8 - A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition - Google Patents
A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition Download PDFInfo
- Publication number
- WO2016004911A8 WO2016004911A8 PCT/CZ2015/000076 CZ2015000076W WO2016004911A8 WO 2016004911 A8 WO2016004911 A8 WO 2016004911A8 CZ 2015000076 W CZ2015000076 W CZ 2015000076W WO 2016004911 A8 WO2016004911 A8 WO 2016004911A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cocrystal
- pharmaceutical composition
- mandelic acid
- ivabradine hydrochloride
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a new solid form of ivabradine hydrochloride and (R)-mandelic acid of formula (II) hi the molar ratio of 1:1. The method of preparing the above mentioned cocrystal consists in mixing or grinding the individual components in the presence of a solvent The present invention also relates to a polymorphically stable pharmaceutical composition and a granulate, which contains the cocrystal and a pharmaceutically acceptable excipient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2014-478A CZ305436B6 (en) | 2014-07-10 | 2014-07-10 | Solid form of ivabradine hydrochloride and (R)-mandelic acid and pharmaceutical composition thereof |
CZPV2014-478 | 2014-07-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016004911A1 WO2016004911A1 (en) | 2016-01-14 |
WO2016004911A8 true WO2016004911A8 (en) | 2016-05-19 |
Family
ID=53765011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2015/000076 WO2016004911A1 (en) | 2014-07-10 | 2015-07-10 | A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition |
Country Status (2)
Country | Link |
---|---|
CZ (1) | CZ305436B6 (en) |
WO (1) | WO2016004911A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220024924A1 (en) * | 2018-11-27 | 2022-01-27 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681862B1 (en) | 1991-09-27 | 1993-11-12 | Adir Cie | NOVELS (BENZOCYCLOALKYL) ALKYLAMINES, THEIR PREPARATION PROCESS, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2868777B1 (en) | 2004-04-13 | 2006-05-26 | Servier Lab | NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID |
FR2882554B1 (en) | 2005-02-28 | 2007-05-04 | Servier Lab | IVABRADINE HYDROCHLORIDE BETA D-CRYSTALLINE FORM, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882556B1 (en) | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE GAMMA D FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882555B1 (en) | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882553B1 (en) | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2891826B1 (en) | 2005-10-11 | 2007-12-28 | Servier Lab | CRYSTALLINE FORM 6 OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2891827B1 (en) | 2005-10-11 | 2007-12-28 | Servier Lab | CRYSTALLINE DELTAD FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
ATE544754T1 (en) | 2006-11-30 | 2012-02-15 | Cadila Healthcare Ltd | METHOD FOR PRODUCING IVABRADINE HYDROCHLORIDE |
RU2473544C2 (en) * | 2007-05-30 | 2013-01-27 | Инд-Свифт Лабораториз Лимитед | Method of producing ivabradine hydrochloride and polymorphs thereof |
CN101774969B (en) | 2009-01-13 | 2012-07-04 | 江苏恒瑞医药股份有限公司 | Ivabradine sulfate and method for preparing type I crystal thereof |
SI23290A (en) | 2010-02-12 | 2011-08-31 | Krka D.D., Novo Mesto | New forms of ivabradine hydrochloride |
WO2011104723A2 (en) * | 2010-02-23 | 2011-09-01 | Ind-Swift Laboratories Limited | Acid addition salts of ivabradine and preparation thereof |
US20130084335A1 (en) * | 2010-06-14 | 2013-04-04 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition |
US9440924B2 (en) * | 2011-08-02 | 2016-09-13 | Sandoz Ag | Acetone solvate of ivabradine hydrochloride |
EP2589594A1 (en) | 2011-11-04 | 2013-05-08 | Urquima S.A. | Ivabradine hydrochloride Form IV |
CZ305096B6 (en) * | 2013-10-02 | 2015-04-29 | Zentiva, K.S. | Ivabradine hydrochloride and (S)-mandelic acid solid form and pharmaceutical composition thereof |
-
2014
- 2014-07-10 CZ CZ2014-478A patent/CZ305436B6/en not_active IP Right Cessation
-
2015
- 2015-07-10 WO PCT/CZ2015/000076 patent/WO2016004911A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CZ2014478A3 (en) | 2015-09-16 |
WO2016004911A1 (en) | 2016-01-14 |
CZ305436B6 (en) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
WO2014014835A8 (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
TN2017000521A1 (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
UA109868C2 (en) | N -alkyltriazole compounds asr | |
MD20140072A2 (en) | New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them | |
WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
WO2011157722A3 (en) | Solid ivabradine-containing composition | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2011146583A3 (en) | Nanoparticulate cinacalcet formulations | |
WO2015110897A3 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
HK1243424A1 (en) | Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof | |
WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
WO2016071435A3 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
WO2017177004A8 (en) | Tertiary amides and method of use | |
WO2012070062A3 (en) | Novel polymorph of nilotinib hydrochloride | |
MX2020002123A (en) | Ribociclib salts and solid state forms thereof. | |
WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
IN2013MU02206A (en) | ||
PH12019500822A1 (en) | Crystalline forms of eravacycline | |
WO2016092561A3 (en) | Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof | |
WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
EP3564224A3 (en) | Crystalline form of vortioxetine hydrobromide as antidepressant drug | |
EP2871187A4 (en) | Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | |
WO2015002755A3 (en) | Compounds for the treatment of malaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15744868 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15744868 Country of ref document: EP Kind code of ref document: A1 |